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The objective of this study was to compare clinical outcomes and oral microbiome 
changes following comprehensive dental care in HIV+ patients. 
Twenty-seven HIV+ patients received periodontal treatment, oral hygiene instructions, 
caries control, and extraction of hopeless teeth. Systemic (viral load, CD4 counts, ART regimen) 
and oral clinical parameters (presence of caries, gingival and plaque indices) were measured at 
baseline (BL), 12-months (12M), and 24-months (24M) after therapy. Differences between 
clinical and microbial parameters between BL, to 12M, or 24M were determined. 
Factors associated with changes in relative abundance of bacterial genera include 
smoking status, CD4 counts, and anti-retroviral mediation status. Several genera appear to be 
driving changes including Megasphaera, Kingella, Veillonella, and Prevotella. After one year of 
dental treatment, the oral microbiome shifts to a more HIV-negative, health-associated 
microbiome with increased alpha diversity of genera. This change in diversity plateaus in the 
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CHAPTER 1: THE INTERFACE OF BACTERIA AND VIRUSES IN DISEASE 
 
Introduction 
Periodontal disease, colloquially referred to as gum disease, consists of a range of diseases 
and infections that affect the supporting structures of teeth. These structures, known as the 
periodontium, consist of the gingiva, alveolar bone, the periodontal ligament, and the cementum 
on the tooth surface and serve as the foundation of the dentition. Diseases of the periodontium 
range from slight edema and bleeding of the gingiva to severe inflammation with destructive 
alveolar bone loss.  
 
Section 1.1 Periodontal Disease: Disease Process and Clinical Manifestations 
 
Microbial etiology of periodontal disease 
Several theories have been proposed over the years regarding the pathogenesis of 
periodontal infections. The overarching theme is that this infection is initiated by bacteria and 
modulated by the host’s response. Sigmund Socransky postulated that bacteria was the 
etiological agent of periodontal disease.1 Socransky emphasized that it was difficult to elucidate 
this etiology due to the slow rate of progression of periodontal disease, variation in host 
resistance, lack of a sufficient animal model to study the disease, complexity of the 
microorganisms that may be difficult to cultivate outside of the mouth, and the many clinical 
variations in the presentation of disease.1
2 
Some of the evidence for the bacterial etiology of periodontal disease includes a 
correlation between the amount of bacterial debris (plaque) with the severity of gingivitis, 
correlation of plaque and bone loss, histologic correlation of gingival inflammation with 
presence of bacterial plaque and clinical observation that periodontal therapy can stop or delay 
periodontal destruction.1 The implications of plaque control for periodontal health were 
examined in a classic study by Loe et al.2 in which gingivitis was induced in a group of 12 
healthy subjects. In the study, subjects were given instructions to refrain from brushing their 
teeth and to eliminate any use of oral hygiene aids. These subjects were examined at varying 
time intervals to reassess their plaque indices and their gingival status. When inflammatory 
changes were observed, subjects were then given detailed instructions in oral hygiene methods 
using a toothbrush and wood massage stick. Results from this study showed that when tooth 
cleansing stopped, bacterial plaque increased significantly and gingivitis was induced within 7-
21 days. When regular oral hygiene measures resumed, subjects returned to gingival health 
within 7-10 days.  
 
Microbial pathogenesis of periodontal disease 
How bacteria influence the initiation and progression of periodontal disease is described 
by several theories. The different theories of pathogenesis are labeled as Non-Specific, Specific, 
Ecological, and Keystone and relate to their defining characteristic for the role of bacteria.  
The Non-Specific Plaque Hypothesis states that plaque accumulation, regardless of 
specific bacterial composition, is responsible for periodontal disease.3 Increases in the number of 
microorganisms, usually native to the oral environment in both health and disease, and changes 
in their proportions are more relevant than changes in a single species. All bacteria found in 
plaque have virulence factors that contribute to the pathogenic potential of plaque. The one 
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exception to this is with specific forms of periodontal disease including what was previously 
called” juvenile periodontitis” and acute necrotizing disease. Treatment under this hypothesis 
requires elimination of all plaque and prevention focuses on plaque control.3 
The Specific Plaque Hypothesis states that discrete combinations or complexes of 
bacteria are most important for the development of disease.4 This hypothesis is based on more 
sophisticated microbial identification techniques. It seeks to refine treatment to more targeted 
techniques to eliminate or control the bacteria responsible for the most change in clinical 
parameters.   
The Ecological Plaque Hypothesis subsequently became popular and it states that there is 
an ecological imbalance which allows for a shift to more disease causing bacteria.5,6 This theory 
now looks at the bacterial species in the context of the environment, or host, in which they 
reside. If the environment is conducive to the growth and proliferation of certain species, then 
these species will proliferate and dominate the local environment. This relates to periodontal 
disease where an established periodontal lesion may change the local environment of the 
periodontium by causing localized bone loss and increases in inflammation of the gingiva. This 
area of increased blood flow, exposure of heme products, and establishment of an anaerobic 
environment due to pocketing of the gingival sulcus can tip the balance to a more pathogenic 
species type that accelerates periodontal destruction. 
Most recently, the Keystone-Pathogen Hypothesis has been adopted which proposes that 
certain species, even in low abundance, can cause disease by interfering with the immune system 
and causing shifts in the ecological community.7 It is the host’s immune system that causes the 
irreversible damage on the periodontium. Specifically, Porphyromonas gingivalis, has been 
hypothesized to be the keystone pathogen that alters the innate immunity and initiates the 
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destruction of the periodontium.8 P. gingivalis can subvert the immune system through secretion 
of interleukin-8 (IL-8), complement activity, and Toll-like receptor 4 (TLR4) activation. In this 
state, the immune system is impaired and cannot act to regulate the usual oral commensal 
bacteria present. This dysbiotic state is the first step in the sequele of destructive inflammation 
and subsequent bone loss in the periodontium.8  
These shifts in paradigm in the microbial pathogenesis of periodontal diseases developed 
concurrently with innovations in more advanced microbial identification techniques independent 
of culturing. Ultimately, though, there is still more to be explored and learned in this field.  
 
Immunological pathogenesis of periodontal disease  
After the acknowledgement that bacteria play an important role in the initiation of 
periodontal disease, Page and Schroeder explored how a periodontal lesion progresses.9 They 
described periodontal disease as a chronic inflammatory disease with an intricate interplay 
between microbial challenge and immunological response, including four stages: Initial, Early, 
Established, and Advanced lesions.  
The “initial lesion” typically develops 2-4 days after plaque accumulates. This lesion is 
characterized by edema with increased gingival crevicular fluid (GCF), polymorphonuclear 
neutrophil (PMN) accumulation, and loss of connective tissue. In the absence of tooth brushing, 
an acquired pellicle forms on the hard structures of teeth.  This pellicle is formed from 
glycoproteins in saliva and promotes the colonization of Streptococci. Lipoteichoic acid and 
peptidoglycans found in the cell walls of these Streptococci then activate the immunological 
response in the gingival sulcus through the alternative pathway. In this pathway, C3a and C5a 
proteins from complement stimulate the release of vasoactive amines from mast cells in the 
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surrounding gingival tissues of the dento-gingival junction. This leads to increased vascular 
permeability and edema. Additionally, tumor necrosis factor alpha (TNF-α) is released and 
increases the expression of adhesion molecules by endothelial cells. This causes PMNs to 
accumulate in the tissue and subsequently release enzymes that contribute to connective tissue 
destruction, release neutrophil extracellular traps (NETs) which help trap and destroy pathogens, 
and release pro-inflammatory cytokines such as interleukin  1 (IL-1) and interleukin 17 (IL-17).10 
After 4-7 days, the “early lesion” shows continued vascular changes and even more of an 
increase in GCF. In this lesion, lymphocytes and macrophages now predominate over PMNs and 
there is a surge in inflammatory response. This lesion is still a localized lesion but there is 
continued connective tissue destruction in the gingiva and in the junctional epithelium. 
Interleukin 8 (IL-8) is also released by epithelial cells and acts as a chemoattractant for more 
neutrophils to migrate into the area of the lesion.  
Within 2-3 weeks, the “established lesion” is considered the transitional phase between 
gingivitis and periodontitis. At this stage, increases in the proportions of B-cells and plasma cells 
predominate. While some patients may remain in a stable gingivitis state, a proportion of patients 
will progress into the more destructive periodontitis state of continued inflammation and 
progressive bone loss. The integrity of the epithelium of the sulcus has deteriorated and the 
ulceration of this lining allows for increased penetration of microbial substances and production 
of IL-1 and TNF-α.  
 The “advanced lesion” has a similar cellular profile as the established lesion but there is 
now loss of the attachment apparatus through continued tissue destruction. Inflammatory 
cytokines IL-1, IL-6, TNF-α, and prostaglandin E2 (PGE2) stimulate fibroblasts to produce 
matrix metalloproteases (MMPs) that are able to degrade the collagen in the extracellular matrix. 
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As the collagen is cleaved, it is denatured and phagocytosed by fibroblasts leading to ongoing 
destruction of the periodontium. Progressive tissue and bone loss is characteristic of this stage. 
 
Immune regulation in periodontal disease 
The immune system plays an important role in regulating the homeostasis between the 
host and the microbe that has infected the host. In periodontitis, it has been postulated that the 
microbes associated with disease are proficient in exploiting this immune surveillance for the 
purposes of causing bone loss and dysbiosis.11 In periodontal disease, the innate and adaptive 
immune response play an important role in protective regulation and destructive progression of 
disease.  
A stable gingivitis lesion may reflect a protective immunological host response, when 
initiating inflammation to clear the body of this infection.12 In the initial lesion, PMNs synthesize 
and secrete both pro-inflammatory and anti-inflammatory immunoregulatory molecules like 
interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-
8), and IL-1 receptor antagonist (IL-1ra).13 These cytokines can then influence PMNs or 
influence a wide range of cells including B cells, T cells, macrophages, fibroblasts, and 
endothelial cells.13 In an early lesion, the activation of a cell-mediated inflammatory response 
and the secretion of type 1 helper T-cell (Th1) cytokines facilitate the recruitment of 
macrophages to destroy intracellular and extracellular pathogens.14  
The severity of subsequent periodontitis may reflect an altered host immune, 
inflammatory, and regenerative response based on congenital, environmental, or age-related 
factors.11 When a lesion shifts from stable to progressive, a shift from Th1 to Th2 cytokines can 
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be seen. Th2 cytokines are associated with the stimulation of mast cells, eosinophils, and 
immunoglobulin E (IgE).14 
The immunological basis for periodontal disease activation and progression is an 
evolving field of research. Understanding these host-related factors is important in identifying 
susceptible populations to microbial immune subversion or immune activation. By inhibiting 
inflammation at the host level, periodontitis may be treated effectively.11  
 
Periodontal disease progression  
The role of gingivitis as a risk factor for periodontal disease was reinforced by Lang et 
al.15  in a series of longitudinal studies examining healthy males over a 26-year period. Clinical 
measures included plaque index, gingival index, caries index, gingival recession, and loss of 
attachment. Overall, healthy dentition was maintained throughout the study. However, in areas of 
long standing gingivitis, development of periodontitis occurred. Patients placed in the most 
severe gingival index group showed significantly more tooth loss over time. This led to the 
conclusion that gingival inflammation is a risk factor for tooth loss. In fact, teeth with healthy 
tissue were at 8.4 times lower risk of loss compared to minimal inflammation and at 45.8 times 
lower risk of loss compared to chronic inflammation.  
 
Section 1.2 Viruses and Periodontal Disease 
 
Both exogenous and endogenous factors can affect the manifestation and progression of 
periodontal diseases.16 These factors help describe the host environment that may significantly 
alter disease progression. Tobacco smoking is an example of an exogenous factor and genetic 
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variations in inflammation is an example of an endogenous factor.  Additionally, host 
coinfection, with certain viruses, has been studied to understand how host immunological 
defenses are affected by both viral and bacterial challenge. Herpes viruses, Papilloma viruses, 
and Human Immunodeficiency Virus (HIV) are among the most commonly studied in the 
context of periodontal diseases.  
 
Periodontal disease and Herpes viruses 
Herpes viruses, including herpes simplex viruses (HSV-1 and HSV-2), Epstein-Barr virus 
(EBV), and Cytomegalovirus (CMV), are prevalent in a large portion of the population. They are 
present at higher frequency in gingival tissue of periodontitis sites versus healthy sites and are 
also found in higher frequency in the GCF of periodontally diseased sites than from gingivitis or 
healthy sites.16 Contreras et al.17 has shown that CMV DNA, EBV DNA, HSV DNA was found 
more frequently in biopsies of gingival tissue from periodontitis sites than in biopsies of tissue 
from healthy sites. Additionally, Parra and Slots18 have shown that GCF collected from 
periodontitis patients shows a significant incidence of CMV, EBV, HSV, Human papilloma virus 
(HPV), or Human immunodeficiency virus (HIV). Saygun et al.19 similarly showed an increase 
in CMV and EBV-1 in subgingival plaque samples at sites with increased probing depths and 
attachment loss.  
 
Periodontal disease and Human papilloma virus 
HPV infection occurs at oral mucosal surfaces and may result in the development of warts or 
in malignancy. Due to the anatomy of the gingival pocket, it serves as a site of possible entry of 
HPV in the oral mucosa. HPV targets basal cells in mucosal sites and it has been shown that high 
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risk HPV types have been found in these tissues. HPV 6, 11, and 16 DNA or related DNA have 
been found in periodontal tissues.20 This suggests that the periodontal pocket can serve as a 
reservoir for HPV and may be related to the initiation of periodontal disease through 
proliferation of epithelial cells in the junctional epithelium.21 
 HPV reservoirs have implications for oro-pharyngeal squamous cell carcinoma (OPSCC). 
HPV16 has been detected in 90% of HPV related OPSCC. A mix of high risk (HR)- and low risk 
(LR)- HPV types have been detected in hyperplastic oral lesions.22 While the high-risk HPVs are 
consistently identified in OPSCC, low-risk HPVs cause genital tract, oral cavity, and respiratory 
tract benign hyperplastic lesions. Although low-risk HPVs are regarded as non-oncogenic agents, 
they have been detected in OPSCC and oral squamous cell carcinoma (SCC) lesions. HPV 6 has 
been found in tonsil carcinoma and oral biopsies with histologic evidence of papillomatosis.23   
 
Periodontal disease and HIV 
 Since the 1980s, the biological and social impact of HIV has been studied in detail. HIV 
causes  immune system modification and has possible implications for periodontal disease clinical 
presentation and progression.24 Most notably, periodontal diseases such as linear gingival 
erythema (LGE), necrotizing gingivitis (NG), and necrotizing periodontitis (NP) have shown an 
increased prevalence among patients with HIV16. In HIV positive patients, the prevalence of 
chronic periodontitis ranges from 5-69%, which may be higher than the general population and 
suggests that HIV infection may predispose patients to a more severe chronic periodontitis.16,25  
 The evidence for the role of a HIV infected host in periodontal disease presentation shows 
that HIV seropositivity does not necessarily predict periodontal disease progression.24 More 
importantly, cluster of differentiation 4 (CD4) counts are significant in the clinical presentation of 
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periodontal disease suggesting a role of impaired immune function in severity of periodontal 
disease.26 In severely immunocompromised patients with CD4 counts <200 cells/ul, less 
periodontal disease is seen because of a dysfunctional immune response. In patients with CD4 
counts between 200 and 500 cells/ul, there is a linear association between CD4 count and 
periodontal indices of bleeding, probing depth, and attachment loss. CD4 cell counts above 500 
cells/ul showed a normal immune response and level of CD4 cell count did not affect periodontal 
clinical incidences.27 Similarly, significant improvements in periodontal clinical parameters such 
as clinical attachment level gain and probing pocket depth reduction are associated with 
improvements in CD4 counts. Thus, periodontal therapy may have a reciprocal impact on 
improving HIV status.28  
 
Section 1.3 HIV: Disease Process and Clinical Manifestations 
 
HIV is a viral infection that affects more than 36 million people worldwide.29 Through the 
implementation of rigorous antiretroviral therapy (ART) medications, HIV has been considered, 
for many years, a chronic disease that is characterized by systemic immune activation.30 After 
infection, there is an increase in proinflammatory cytokines, low CD4/CD8 ratios, and exhausted 
T cells and monocytes.31,32  Chronic coinfections also influence the chronic inflammatory state of 
people living with HIV and predisposes patients to non-infectious comorbidities like cancer and 
cardiovascular diseases.33,34 Eradication of the virus has been difficult due to the ability of HIV 
to insert its genome into the host’s genome to escape immune surveillance and its persistence in 
low levels in tissues acting as latent viral reservoirs.34 
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Gut microbiome research 
A wide breadth of knowledge exists in regards to the enteric environment of patients with 
HIV. It has been shown that HIV infection is associated with pathologies of the intestine 
including inflammation which can change the local environment of the gut.35 Changes in the gut 
microbiome and the subsequent translocation of microbial products through compromised 
epithelial barriers has been shown to increase chronic immune activation and HIV disease 
progression.35  
In a population of HIV infected Ugandan individuals, Monaco et al.36 individuals that 
subjects with CD4 cell counts <200 cells/ul had decreased bacterial richness and decreased 
phylogenic diversity versus patients with CD4 cell counts >200 cells/ul or HIV negative patients. 
Additionally, there was no significant difference in beta-diversity based on HIV status or CD4 
cell count. Mutlu et al.37 showed that the lower gastrointestinal tract microbiome was correlated 
with clinical parameters in HIV positive patients. Specifically, the microbiome was less diverse 
and showed decreased numbers of commensal bacteria taxa. No differences were seen in 
diversity between high and low CD4 cell counts or between high and low viral loads.  
 
HIV and viral co-infection 
Oncogenic HPV subtypes are more prevalent in HIV-positive than HIV-negative 
individuals.38  Oral HPV DNA shedding has been detected in 14% to 35% of HIV+ patients and 
was more frequently identified in virologically suppressed HIV-infected patients on ART than 
those who were not suppressed. Likewise, HPV associated disease has been detected and 
increased in the context of HIV.  Oral warts are associated with decreasing HIV-1 RNA. A 
retrospective study of 1,280 HIV patients on highly active antiretroviral therapy (HARRT) from 
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1990 to 1999 detected an increase in oral warts with concurrent reduction in other HIV 
associated lesions including candidiasis, hairy leukoplakia and Kaposi’s sarcoma.39 Importantly, 
compared with general population recent studies detect increasing incidence of HPV-related 
oropharyngeal malignancies in HIV infected individuals, despite, combination antiretroviral 
therapy (ART).40  
 
Section 1.4 Oral Microbiome in Health and Disease 
 
Evolution of bacterial studies/culturing studies 
 Previous knowledge of health and disease associated microbiota was limited by culture 
techniques and media. Samples were plated on selective media and identification of microbes 
relied on microscopy. Advances in the identification of a diverse microbiota is due to culture 
independent methods including cluster analysis, DNA hybridization, and DNA and RNA 
sequencing techniques.41  
 
Microbiome in health 
 The oral microbiome is a complex community of viruses, protozoa, fungi, archea, and 
bacteria that account for about 1000 species.42 In the oral cavity, the oral microbiome present is 
typical for this location but shows great variation in composition based on the individual.43 
Specifically, similarities are mostly seen at the genus level between individuals and less so at the 
species level.44 The phyla Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, 
Spirochaetes, and Fusobacteria account for the majority of the bacteria in the microbiome.42 In a 
healthy individual, the microbiota play a crucial role in “colonization resistance” by occupying 
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space and nutrients to prevent colonization by pathogens.45 This leads to a significant impact of 
the microbiome on maintaining oral and systemic health.41 An example of a health-associated 
bacteria is Streptococcus salivarius strain K12. Through in vitro studies, S. salivarius bacteriocin 
acts as a “natural” antibiotic to inhibit gram-negative bacterial growth.46 
 
Dysbiosis of the microbiome in periodontal disease 
Periodontal disease associated community profiles consist of greater diversity of bacterial 
species.47 Specifically, Spirochaetes, Synergistetes, and Bacteroidetes were more abundant.47 
When correlating clinical parameters of periodontal disease and microbiome characterization, 
inflammation (bleeding on probing, BOP) was not associated with a distinct microbiota but it was 
associated with increased abundance of bacterial species.48 Regardless of inflammation status, sites 
with signs of periodontal destruction did show a change in diversity and a shift in bacterial species, 
when compared to healthy sites. Periodontitis was associated with higher abundance of 
Spirochetes, Synergistetes, Firmicutes, and Chloroflexi.48 More recent studies, categorizing 
patients according to high (BOP >50%) and low (BOP ≤ 50%) status, has shown a difference in 
diversity in health versus disease with high individual diversity.49 With increasing inflammation 
associated with periodontitis, changes in the composition of the microbiota lead to an increased 
diversity associated with known periopathogens such as Treponema, Tannerella, and 
Capnocytophaga.49 
 
Oral microbiome in HIV+ patients 
Because patients with HIV are a susceptible population to periodontal disease, the 
characterization of the microbiome in HIV positive patients has been explored to elucidate novelty. 
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Early studies relied on culture techniques, biochemical tests, and microscopic characterization of 
individual species. In 1989, Murray et al. showed that there was no difference in the bacteria found 
in patients with HIV and chronic periodontitis and patients with “classical periodontitis” but did 
find a difference in microorganisms present in HIV associated gingivitis.50 In this study, that relied 
on culturing techniques and immunoflourencese, Prevotella intermedia and Aggrebacter 
actinomycecomitans were found in high proportion on both HIV associated gingivitis and 
periodontitis relative to the proportions found in health and HIV negative controls. Statistically 
significant differences in flora were associated with HIV+ patients with periodontitis versus HIV- 
patients with periodontitis. Specifically, Mycoplasma salivarium was elevated in HIV+ 
periodontitis patients while Treponema denticola was elevated in HIV- periodontitis patients.51  
Culture-independent techniques, such as 16s DNA sequencing led to advances in the 
characterization of HIV associated microbiome. Differences between HIV status (viral load and 
CD4 counts) and periodontal status (gingivitis or periodontitis) correlated with differences in 
bacterial profiles of patients. Patients with low HIV viral loads and gingivitis presented with more 
Streptococcus. In patients with high HIV viral loads and low CD4 counts, Pseudomonas and 
Neisseria were more common.52 Thus, bacterial and fungal diversity has been shown to correlate 
with different disease status.52  
 
Oral microbiome related to Antiretroviral Therapy (ART) 
HIV positive patients present a unique challenge to characterizing a representative 
microbiome. Significant variables exist between patients and within different time points of the 
same patient due to differing antiretroviral medication regimens, treatment of coinfections with 
antibiotics, and other systemic parameters that may influence the resident bacteria. For example, 
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in a paired oral salivary microbiome study in patients using ART, microbial communities did not 
change over 24 weeks of ART therapy and did not differ significantly from baseline to 24 weeks. 
More significant was the high person to person variability in salivary microbiome and the wide 
range of alpha diversity seen across all samples.53 
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CHAPTER 2: CHANGES AND ORAL MICROBIOME SHIFTS IN HIV+ PATIENTS 
FOLLOWING PERIODONTAL THERAPY 
 
Objective 
It is known that the oral microbiome may shift significantly in the context of 
immunosuppression. The objective of this study is to compare clinical outcomes and microbiome 
changes following comprehensive dental care in HIV+ patients. The current study aims to address 
how HIV status (CD4 count, viral load, ART therapy status) affects the oral salivary microbiome 
of patients with and without periodontal diseases.  
 
Section 2.1 Methods and Materials 
 
Patient population and participants 
 Patients included in this study belonged to a prospective multicenter longitudinal study in 
the Special Projects of the National Significance (SPNS) Oral Demonstration Project.  A total of 
196 patients were enrolled in this multicenter study. A subset of these patients were recruited at 
the University of North Carolina at Chapel Hill (UNC) site. Approval for this study was obtained 
from the UNC Institutional Review Board (IRB) and the Evaluation Center for HIV and Oral 
Health at Boston University.  
 Participants in the study included individuals 18 years or older who did not have any 
dental care for at least 12 months prior to the start of the study. These patients were referred to 
the study from local infectious diseases specialists and community healthcare centers. A total of 
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27 HIV positive patients were recruited for this study and received treatment at the UNC 
Hospital Dental Clinic.  
 
Study design 
 Patients were initially seen for a baseline visit consisting of a comprehensive dental exam 
and interview. Examination included full mouth charting of probing depths (PD), clinical 
attachment levels (CAL), and bleeding on probing (BOP). Patients were given oral hygiene 
instructions. Depending on the periodontal status, patients received either a supragingival scaling 
and polishing or a scaling and root planing debridement. If needed, extractions, restorations, and 
prosthetic rehabilitation were also completed for these patients. Of these individuals, a subset of 
27 patients had whole unstimulated saliva samples collected for microbiological, cytokine, and 
viral analyses.  
 Baseline interviews were performed between January 2008 and August 2011 and 
information related to sociodemographic characteristics, tobacco use, barriers to accessing oral 
health care, and oral hygiene habits in both English and Spanish were collected. Lab results 
related to HIV viral load (HIV VL) and CD4 cell counts were obtained from patient chart 
reviews.  
Systemic (viral load, CD4 counts, ART regimen) and oral clinical parameters (presence 
of caries, gingival and plaque indices) were measured at baseline (BL, visit 1), 12-months (visit 
3), and 24-months (visit 5) after therapy, while patients received periodontal treatment every 6 
months.  At 1-year intervals, unstimulated whole saliva samples were collected from the original 
27-patient subset. Baseline visit 1, visit 3, and visit 5 were included in this study. This study 





Data collection and examiners 
Data collection was completed by calibrated examiners (kappa score >0.9) and inputted 
into a web-based database utilized by each of the multisite centers included in the study. CD4 
counts, HIV VL, and medication status were determined through a medical chart review. 
Periodontal measurements were used to determine extent periodontal involvement and 
periodontal disease severity was determined using the biofilm-gingival interface (BGI) index.54 
BGI categories were assigned as follows: 
BGI 0: biofilm–gingival interface‐healthy (PD ≤3 mm, BOP extent scores <10%) 
BGI 1: BGI‐gingivitis (PD ≤3 mm, BOP extent scores >10%) 
BGI 2: BGI‐deep lesion/low bleeding (PD ≥4 mm, BOP extent scores <10%) 
BGI 3: BGI‐deep lesion/moderate bleeding (PD ≥4 mm, BOP extent scores 10% to 50%) 




The microbial content of the salivary samples collected at baseline, visit 3, and visit 5 
were analyzed by sequencing the 16S rDNA gene V1-V3 hypervariable region using MiSeq 
(Illumina, CA). Sequencing was completed by the UNC Microbiome Core Facility. Marker data 
profiling was completed using the web application MicrobiomeAnalyst.  
 
Variables 
 At baseline, demographic variables (smoking status and HIV medication status), 
periodontal variables (extent bleeding on probing (<30% or >30%), extent attachment loss 4mm 
or greater with bleeding on probing, and BGI),  and HIV status variables (CD4 counts and HIV 
VL values) were used to categorize patients. Outlier values were removed from the samples 
analyzed. 
 Longitudinal measurements of patients at baseline versus 1 year (visit 3) and 1 year 
versus 2 years (visit 5) after initiation of treatment were compared for 23 patients who had all 
microbiological measurements available. 
 Of the subjects included in this longitudinal data, patients were further categorized based 
on whether they showed an increase, decrease, or unchanged value related to CD4 counts, HIV 
VL, and BGI during the period from baseline to 1 year of treatment.  
 
Section 2.2 Statistical Analysis 
 
 Correlations between relative abundance operational taxonomic units (OTUs) and 
metadata parameters at baseline were used for descriptive purposes in this patient population. 
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Linear discriminate analysis (LDA) effect size (LEfSe) was used to identify OTUs that were 
significantly differentially abundant between patients grouped by different baseline periodontal 
or viral parameters. Paired sample t-tests were performed to determine if there were significant 
differences in OTU alpha diversity (Shannon diversity index) between paired patient sampling at 
baseline vs visit 3 and visit 3 vs visit 5.  
 
Section 2.3 Results 
Baseline characteristics 
Patient demographics are presented in Table 2. Relative percentage abundance of 






Smokers versus non-smokers 
Smokers showed a trend for increased Prevotella (+10%) and Veillonella (+8%) and 
decreased Streptococcus (-22%) and Rothia (-6%). Lactobaccillus was present in smokers (8%) 
while absent in non-smokers (Figure 1a). Smokers showed significantly less Streptococcus (p = 
0.008949) and Aggregatibacter (p = 0.045566) and significantly more Veillonella (p = 0.025305) 





HIV Medication Status 
Patients not on ART medication uniquely had Actinomyces (4%) and Neisseria (4%) 
while patients on medication had less Prevotella (-4%), Veillonella (-6%), Pseudomonas (-4%), 
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and Acinetobacter (-3%) (Figure 2a). Porphyromonas (p = 0.014528) and Oribacterium (p = 





Patients with normal CD4 count > 500cells/mm3 showed more Pseudomonas (+5%) and 
Acinetobacter (+5%), while patients with a low CD4 count showed more lactobacillus (+6%) 
(Figure 3a). Megasphaera (p = 0.036213) and Paludibacter (p = 0.04179) were significantly 
reduced in high CD4 count patients while Cloacibacterium (p=0.040904), Dietzia (p=0.040904), 








HIV viral load (VL) 
Patients with undetectable VL showed a similar profile to patients with low VL with a 
trend for predominately more Streptococcus and Prevotella while uniquely showing a high 
percentage of Lactobacillus (6%). Patients with high VL showed more Pseudomonas (+5%), 
Veillonella (+2-4%), and Acinetobacter (+3%) (Figure 4a). Campylobacter (p = 0.036408) and 
Neisseria (p = 0.011733) were significantly higher in patients with undetectable VL while 





Bleeding on Probing (BOP) 
Patients with high BOP showed a trend for more Prevotella (+9%) and less Rothia (-
13%) while uniquely showing high percentage of Lactobacillus (3%), Pseudomonas (7%), and 
Acinetobacter (4%). Patients with low BOP uniquely showed a trend for more Neisseria (6%) 
seen in Figure 5a. Kingella (p = 8.5284E-5), Corynebacterium (p = 0.023014), Neisseria 
(0.035307), and Pyramidobacter (p =0.044401) were significantly higher in patients with low 




Attachment loss ≥ 4mm with BOP 
Patients with high extent AL≥ 4mm with BOP showed a trend for more Streptococcus 
(+30%) and Rothia (+8%) while uniquely showing little to no Prevotella (-14%), Veillonella (-
7%), and Pseudomonas (-6%) (Figure 6a). Shannon alpha diversity index showed greater 
diversity in the low group versus high group (p = 0.043478). Scardovia (p = 0.012) and 




Biofilm-gingival interface (BGI) 
Patients with BGI 0 (healthy) showed a trend for more Streptococcus, and an 
intermediate amount of Rothia compared to BGI 3 and 4. BGI 3 and 4 showed more Prevotella 
and Veillonella, BGI 4 showed more Pseudomonas (10%) and uniquely showed more 
Lactobaccillus (4%) (Figure 7a). Shannon alpha diversity index showed lower diversity in the 
BGI 0 group versus BGI 3 and BG 4 (p = 0.042586). Streptococcus (p = 0.04554) was 
significantly higher in BGI 0 (healthy) while Moryella (p = 0.048447) and Actinomyces (p = 






Changes over time: baseline, visit 3, and visit 5 
Baseline versus visit 3 
 
 Over the course of 12 months, patients showed a decrease in Streptococcus (-4%), 
Prevotella (-2%), and Rothia (-2%) and an increase in Veillonella (+4%). Pseudomonas and 
Acinetobacter stayed stable (Figure 8a). Shannon alpha diversity index diversity increased with 
marginal P value between baseline and visit 3 (paired t-test, p = 0.059) seen in Figure 8b. 
Oribacterium (p = 0.023496) and Haemophilus (p = 0.043037) were significantly higher at visit 






Visit 3 versus visit 5 
Over the subsequent course of 12 months, patients showed an increase in Prevotella (+3%), 
Veillonella (+6%), Pseudomonas (+1%) and decrease in Streptococcus (-2%), Rothia (-2%), and 
Acinetobacter (-1%). Actinomyces was uniquely present at visit 5 (+3%) (Figure 9a). Shannon 
alpha diversity index showed no significant difference between 12 and 24 months (paired t test, p 
= 0.187) seen in Figure 9b. Kingella (p = 0.047847) was significantly higher at visit 5 versus 






Parameter changes occurring during first year of treatment (baseline to visit 3) 
Microbiome changes in relation to CD4 changes from baseline to 12 months 
 
 During the first year of treatment, patients who showed a decrease in CD4 had more 
Pseudomonas (+3%), Veillonella (+7%), and Acinetobacter (+3%). Patients who showed an 
increase in CD4 showed an increase in Porphyromonas (+3%) and Lactobacillus (+2%). In 
Patients who had unchanged CD4, Megasphaera (6%) and Actinomyces (5%) were uniquely 
present (Figure 10a). Patients with unchanged CD4 appeared to be more diverse but Shannon 
alpha diversity index showed no significant difference between groups (t-test, p = 0.22081). 
Mesorhizobium (p = 0.047847) and Actinobacillus (p = 0.038819) was significantly higher in 





Microbiome changes in relation to HIV VL changes from baseline to 12 months 
During the first year of treatment, patients who showed a decrease in HIV VL had 
uniquely more Haemophilus (+3%) and Actinomyces (3%). Patients who showed an increase in 
HIV VL showed an increase in Porphyromonas (+8%) and Pseudomonas (+1%). In patients who 
had unchanged HIV VL, relative proportions were similar except for Lactobacillus (+3%) and 
Veillonella (+8%) which increased (Figure 11a). Patients with increased HIV VL appeared to be 
less diverse but Shannon alpha diversity index showed no significant difference between groups 
(t-test, p = 0.22081). Peptoniphilus (p = 0.018797) and Megasphaera (p = 0.047596) were 
increased in patients who showed a decrease in HIV VL. In unchanged HIV VL patients, 
Actinobacillus (p = 0.0061374) and Campylobacter (p = 0.012427) increased. Haemophilus (p = 
0.047457) and Oribacterium (p = 0.017176) showed increased amounts in patients who 





Microbiome changes in relation to BGI changes from baseline to 12 months 
During the first year of treatment, patients who showed a decrease in BGI showed a 
decrease in Rothia (-2%) and Pseudomonas (-1%) while showing an increase in Veillonella 
(+5%).  Patients who showed no change in BGI, Porphyromonas predominated (13%) while 
Acinetobacter was reduced (-4%) (Figure 11a). Actinobacillus (p = 0.050736) and Oribacterium 
(p = 0.040395) were increased in patients who showed a decrease in BGI. In unchanged BGI 





Section 2.4 Discussion 
 
There is a paucity of studies that examine changes in the oral microbiome, in relation to 
caries and periodontal diseases, in HIV positive populations.55 The major aim of this study was 
to answer the question of whether coinfection with HIV, in both well-managed immune 
competent patients or poorly-managed immunocompromised patients, would cause major 
changes in the salivary microbiome to drive disease in patients with periodontal diseases.  
 
Smokers or patients with lower CD4 counts showed an increase in Megasphaera.  
Megasphaera, in addition to Prevotella and Campylobacter, have been shown to be in 
higher proportions of the oral microbiome and distal gastrointestinal microbiome of HIV positive 
individuals.56 The presence of an altered immune response (lower CD4 counts) or the presence 
of a known risk factor for periodontal disease, smoking, seems to increase the presence of this 
genus. This finding is consistent with studies showing the impact of uncultivatable and 
underappreciated genera in disease.11,57 The genera Prevotella, Megasphaera, Selenomonas and 
Desulfobulbus showed a correlation with disease similar to the correlation seen with red complex 
bacteria.11 Whether this systemic and local risk factor influence the microbiome shifts from 
health to disease would be of interest in further studies. Ganesan et al.58 analyzed subgingival 
plaque samples for unique or similar perturbations related to smoking and diabetes. In fact, the 
presence of a systemic impaired inflammatory state, in addition to the local environment 
changes, induced by smoking lead to a synergistic effect of habitat filtering for a more 
pathogenic profile of microbes.   
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Lactobacillus was present in smokers at higher relative abundance than in non-smokers. 
 Lactobacillus, belonging to the order Lactobacillales, is a Gram-positive facultative 
anaerobic bacteria commonly found in the gut microbiome and is typically associated with a 
protective role. In patients with HIV, higher proportions of Lactobacillales has been associated 
with higher CD4, lower HIV VL, and less systemic immune activation.59 The presence of 
increased Lactobacillus in HIV positive smokers is inconsistent with microbiome studies in 
systemically healthy smokers versus nonsmokers. In a study by Mason et al., smokers were 
found to have a pathogen-rich and commensal-poor microbiome that creates “an at-risk-for-harm 
environment.”60 Perhaps the relation between increased lactobacilli in smokers is related to a 
decrease in salivary secretion and not a shift to a more health-associated microbiome.61 
 
Microbiome shifts relative to ART medication status are consistent with microbiome shifts 
seen in the lungs.  
Patients naïve to ART showed an increase in Streptococcus and Actinomyces relative 
abundance while patients on ART showed increases in Rothia. These changes in relative 
abundance are consistent with published studies in the lung microbiome.62 Additionally, the 
increased presence of Porphyromonas in patients not on ART medication suggests that these 
patients have a microbiome primed for inflammation and the manifestation of periodontal 
disease. Without species level analysis of the microbiome, it may be difficult to conclude 
whether ART naïve patients are more susceptible to periodontal disease due to their primed 
periodontal pathogen microbiome.  
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Periodontal health (BOP <30%, BGI 0) in HIV positive patients was seen frequently with 
increased Kingella and Neisseria. HIV positive patients showing signs of gingivitis and 
periodontitis show increased Moryella and Scardovia. 
 While Kingella and Neisseria were more prevalent in these patients with gingival health 
at baseline, studies have shown these two genera to be more associated with periodontitis in HIV 
positive patients.63 Even though these patients have minimal inflammation, their viral status may 
have a greater effect on driving increases in more pathogenic or disease associated genera.    
 
With periodontal treatment, patients appear to be shifting to a more health associated, 
increased alpha diversity profile.   
Overall relative abundance changes were small between baseline and 12 months even 
though patients saw an overall improvement in clinical periodontal parameters. Changes mostly 
consisted of increases in Veillonella and decreases in Rothia and Prevotella. Both Veillonella and 
Prevotella are genera associated with inflammation in HIV populations and the persistence of 
Veillonella has been shown even after 3 years of ART therapy.56,64 
The change in alpha diversity was statistically significant. As measured by the Shannon 
diversity index, at 12 months patients appeared to have an increase in species richness and 
evenness as compared to baseline. This finding is consistent with studies in the gut and lung 
microbiome of HIV-positive patients. Studies show that in untreated HIV patients, alpha 
diversity decreases with more advanced HIV states.56,62 In the salivary microbiome, Shannon 
diversity index has been shown to decrease in HIV-positive patients compared to HIV-negative 
patients.65 When comparing HIV-negative and HIV-positive individuals, Shannon alpha 
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diversity is more diverse in uninfected patients.64 This suggests that with periodontal treatment, 
patients appear to be shifting to a more health-associated, increased alpha diversity profile.    
 The magnitude of differences seen in alpha diversity between baseline and 12 months are 
no longer seen between 12 and 24 months. This suggests that the greatest health associated shifts 
in the oral salivary microbiome appear to occur within the first year of treatment and then plateau 
during the following year.  
 
Increased environmental associated genera are present during first year of treatment. 
In the patients who showed a lack of improvement in their HIV status after 12 months of 
dental intervention (decreased or unchanged CD4 and increased or unchanged HIV VL), 
Mesorhizobium and Actinobacillus appeared to be present in greater amounts than in other 
groups. In patients where periodontal parameters like BGI stayed the same, despite dental 
treatment over 12 months, Porphyromonas was seen in greater proportions consistent with 
patients who are not HIV positive. Interestingly though, Mesorhizobium is again significantly 
increased in patients with unchanged BGI. Mesorhizobium is a gram negative, aerobic, motile 
proteobacteria commonly found in soil or on plants. This genera has been characterized and 
described as ‘exotic’ when found in the oral environment. It has been speculated that ‘exotic’ 
genera or species may be close relatives to species that have not been sequenced yet in the mouth 






Section 2.5 Limitations and future directions 
 
Limitations of the study include the utilization of salivary samples for microbiome 
profiling. Saliva provides a more convenient sampling method and has been used in other studies 
to help characterize the microbiome of both healthy and HIV positive individuals.67,68 Even so, 
there are significant differences between microbiome characterization of plaque and saliva. In a 
study by Kistler et al. in HIV-positive and HIV-negative subjects, principal coordinate analysis 
was used to show a significant separation of plaque and saliva samples when looking at 
community membership and structure. The study concluded that the oral microbiome of HIV-
positive and HIV-negative patients were similar at the species level of characterization. In the 
present study we see a difference over time in the predominate genera in HIV-positive versus 
HIV-negative individuals. In future studies, the inclusion of plaque sample analysis will be 
important to parse out differences or similarities at a species level between these groups of 
patients.  
 In the present study design, healthy, HIV-negative patient controls were not included. 
Analysis of the results at the genera level of characterization of this patient population were 
compared to published studies in other patient populations that included healthy controls. In 
future microbiome analysis, healthy control sequencing will be important for strengthening our 
conclusions of unique presence of bacteria in HIV-positive patients. Sequencing of a negative 
control may also help to explain or discredit the increased presence of environmental or ‘exotic’ 
genera.  
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Section 2.6 Conclusion 
 
 In the oral microbiome of patients with HIV, factors associated with changes in relative 
abundance of bacterial genera include smoking status, CD4 counts, and anti-retroviral mediation 
status. Several genera appear to be driving these changes including Megasphaera, Kingella, 
Veillonella, and Prevotella. After the initiation of dental treatment and one year of maintenance, 
the oral microbiome shifts to a more HIV-negative, health-associated microbiome with increased 
alpha diversity of genera. This change in diversity plateaus in the second year of treatment in a 
well-maintained population. Thus, oral health intervention can have a significant and positive 
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